

**PALM INTRANET**

Day : Tuesday  
Date: 5/4/2004  
Time: 12:50:47

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

## Refine Search

### Search Results -

Term	Documents
FACTOR	806121
FACTORS	633685
IX	194796
ICES	41438
IXES	3498
INTRON	18785
INTRONS	18301
VIII	231965
VIIIS	593
((FACTOR ADJ IX ADJ INTRON) SAME (FACTOR ADJ VIII)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12
((((FACTOR ADJ IX) ADJ INTRON) SAME (FACTOR ADJ VIII)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Tuesday, May 04, 2004   [Printable Copy](#)   [Create Case](#)

**Set Name**   **Query**  
 side by side

**Hit Count**

**Set**  
**Name**  
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;  
 OP=AND

L5 ((Factor adj IX) adj intron) same (Factor adj VIII)  
L4 L2 not L3  
L3 L2 and (Factor adj VIII)  
L2 (Factor adj IX) same (Intron adj 1)  
L1 Negrier-claude.in.

12 L5  
10 L4  
20 L3  
30 L2  
7 L1

END OF SEARCH HISTORY

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)  
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES  
PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS?

### Status: Signing onto Dialog

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Connected

Dialog level 04.06.01D

Last logoff: 03may04 16:41:37

Logon file001 04may04 12:43:25

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

--File 654 - US published applications from March 15, 2001 to the  
present are now online. Please see HELP NEWS 654 for details.

\*\*\*

--File 581 - The 2003 annual reload of Population Demographics is  
complete. Please see Help News581 for details.

\*\*\*

--File 990 - NewsRoom now contains February 2003 to current records.  
File 992 - NewsRoom 2003 archive has been newly created and contains  
records from January 2003. The oldest months's records roll out of  
File 990 and into File 992 on the first weekend of each month.  
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new  
OneSearch category.

\*\*\*

--Connect Time joins DialUnits as pricing options on Dialog.  
See HELP CONNECT for information.

\*\*\*

\*\*\*

--SourceOne patents are now delivered to your email inbox  
as PDF replacing TIFF delivery. See HELP SOURCE1 for more  
information.

\*\*\*

--Important Notice to Freelance Authors--  
See HELP FREELANCE for more information

\*\*\*

NEW FILES RELEASED

\*\*\*AeroBase (File 104)

\*\*\*DIOGENES: Adverse Drug Events Database (File 181)

\*\*\*World News Connection (File 985)

\*\*\*Dialog NewsRoom - 2003 Archive (File 992)

\*\*\*TRADEMARKSCAN-Czech Republic (File 680)

\*\*\*TRADEMARKSCAN-Hungary (File 681)

\*\*\*TRADEMARKSCAN-Poland (File 682)

\*\*\*

UPDATING RESUMED

\*\*\*

RELOADED

\*\*\*Medline (Files 154-155)

\*\*\*Population Demographics -(File 581)

\*\*\*CLAIMS Citation (Files 220-222)

REMOVED

\*\*\*

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<

\*\*\*\*

KWIC is set to 50.  
HIGHLIGHT set on as '\*'

\*  
\*

\* ALL NEW CURRENT YEAR RANGES HAVE BEEN \* \* \*  
\* \* \* INSTALLED \* \* \*  
\*

File 1:ERIC 1966-2004/Apr 29  
(c) format only 2004 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

Cost is in DialUnits

?b 155, 5, 73

04may04 12:43:36 User259876 Session D617.1

\$0.33 0.095 DialUnits File1

\$0.33 Estimated cost File1

\$0.05 TELNET

\$0.38 Estimated cost this search

\$0.38 Estimated total session cost 0.095 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2004/Apr W4

(c) format only 2004 The Dialog Corp.

**\*File 155: Medline has been reloaded. Accession numbers**  
have changed. Please see HELP NEWS 154 for details.

File 5:Biosis Previews(R) 1969-2004/Apr W4

(c) 2004 BIOSIS

File 73:EMBASE 1974-2004/Apr W4

(c) 2004 Elsevier Science B.V.

Set	Items	Description
-----	-------	-------------

---	-----	-----
-----	-------	-------

?s (Factor (w) IX (w) intron) (s) (Factor (w) VIII)

2127311 FACTOR

66580 IX

64321 INTRON

2127311 FACTOR

82024 VIII

S1 3 (FACTOR (W) IX (W) INTRON) (S) (FACTOR (W) VIII)

?rd

...completed examining records

S2 3 RD (unique items)

?t s2/3,k/all

2/3,K/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014794373 BIOSIS NO.: 200400161714

**The core of the factor IX intron I contains a specific sequence that help  
in \*factor\* \*VIII\* production.**

AUTHOR: Plantier Jean-Luc (Reprint); Ducasse Cecile (Reprint); Rodriguez  
Marie-Helene (Reprint); Rolli Veronique (Reprint); Enjolras Nathalie  
(Reprint); Negrier Claude (Reprint)

AUTHOR ADDRESS: Laboratoire d'Hemobiologie, Faculte Laennec, EA 1508,  
Universite Lyon I, Lyon, France\*\*France

JOURNAL: Blood 102 (11): p91b November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of  
Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

**The core of the factor IX intron I contains a specific sequence that help in \*factor\* \*VIII\* production.**

ABSTRACT: We have demonstrated that the introduction of a truncated factor IX intron 1 (TFIXI1; 312 bp) in the \*factor\* \*VIII\* (FVIII) cDNA could lead in CHO cells to a 13 time increase in FVIII production (Plantier et al. Thromb. Haemost. 2001. 86). To determine the...

...introns of the human Apolipoprotein A1 (209 bp) and beta-globin (142 bp) were cloned and inserted at the same locations than TFIXI1 (e.g. \*factor\* \*VIII\* intron 1 and 13), resulting in the constructs F8-A and F8-B. Different chimeric constructs were also generated consisting of (i) two constructs containing...

...culture medium was assessed using an ELISA kit. The intronpossessing constructs that were spliced (F8-9 and F8-A9A) where the only ones that allowed \*factor\* \*VIII\* production. The levels of production were higher than for a construct without intron, as already demonstrated. The results were identical in the two cell lines...

2/3,K/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013593413 BIOSIS NO.: 200200186924

**High-level gene expression of human factor VIII in vivo was achieved by a liver-specific construct containing ApoE-HCR and a heterologous intron**

AUTHOR: Miao Carol H (Reprint); Ye Xin (Reprint); Thompson Arthur R (Reprint)

AUTHOR ADDRESS: Medicine, Puget Sound Blood Center, University of Washington, Seattle, WA, USA\*\*USA

JOURNAL: Blood 98 (11 Part 1): p425a November 16, 2001 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: contain 1) a hepatic locus control region from ApoE gene (ApoE-HCR), 2) a liver-specific alphas1-antitrypsin promoter (HP), 3) a 1.4kb truncated \*factor\* \*IX\* \*intron\* (I) or a synthetic minx intron (mI), followed by 4) a multiple cloning site for inserting cDNA sequences, and 5) a bovine growth hormone polyadenylation signal (A) to make pBS-HCRHPI-A or pBS-HCRHPmI-A. A B-domain deleted \*factor\* \*VIII\* cDNA was inserted into the multiple cloning sites of these two vectors. One day after rapid injection of 50 mug of the constructs, pBS-HCRHPI...

...into the tail vein of mice (n=6/each group), range of 2-25.5 mug/ml and 0.7-5 mug/ml of human \*factor\* \*VIII\* circulated, respectively (normal=0.1mug/ml in human plasma). A control plasmid, pBS-HP-FVIII A, without the ApoE-HCR or an intronic sequence, produced levels...

...that combination of ApoE-HCR and a heterologous intron, either a truncated human factor IX first intron or a synthetic minx intron inserted 5' to \*factor\* \*VIII\* cDNA can greatly enhance \*factor\* \*VIII\* gene expression in vivo. It will be of interest to investigate whether the expression can be further enhanced by inserting a heterologous intron or \*factor\* \*VIII\* introns into different positions in the vector.

Furthermore, the liver-specific vectors can be used to deliver heterologous genes for high-level transgene expression. These high-expressing human \*factor\* \*VIII\* cassettes can be readily inserted into viral or nonviral vectors for achieving effective gene therapy of hemophilia A.

2/3,K/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0013292833 BIOSIS NO.: 200100464672

**Modified factor VIII cDNA**

AUTHOR: Negrier Claude (Reprint); Plantier Jean Luc

AUTHOR ADDRESS: Irigny, France\*\*France

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1249 (1): Aug. 7, 2001 2001

MEDIUM: e-file

PATENT NUMBER: US 6271025 PATENT DATE GRANTED: August 07, 2001 20010807

PATENT CLASSIFICATION: 435-3201 PATENT ASSIGNEE: Aventis Behring GmbH,  
Marburg, Germany PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: A modified Factor VIII cDNA is described comprising deletion of the B-domain and insertion of at least one truncated \*Factor\* \*IX\* \*intron\* 1 in the \*Factor\* \*VIII\* cDNA. The modified \*Factor\* \*VIII\* cDNA may be used for the production of a high yield of \*Factor\* \*VIII\* in vitro. The modified \*Factor\* \*VIII\* cDNA may be incorporated into a vector for gene therapy.

?ds

Set	Items	Description
S1	3	(FACTOR (W) IX (W) INTRON) (S) (FACTOR (W) VIII)
S2	3	RD (unique items)
?s (modified or chimeric) (w) (Factor (w) VIII)		
	471237	MODIFIED
	60854	CHIMERIC
	2127311	FACTOR
	82024	VIII
S3	16	(MODIFIED OR CHIMERIC) (W) (FACTOR (W) VIII)
?s s3 and (Factor (w) IX (w) intron)		
	16	S3
	2127311	FACTOR
	66580	IX
	64321	INTRON
	8	FACTOR (W) IX (W) INTRON
S4	1	S3 AND (FACTOR (W) IX (W) INTRON)
?t s4/3,k/all		

4/3,K/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0013292833 BIOSIS NO.: 200100464672

**\*Modified\* \*factor\* \*VIII\* cDNA**

AUTHOR: Negrier Claude (Reprint); Plantier Jean Luc

AUTHOR ADDRESS: Irigny, France\*\*France

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1249 (1): Aug. 7, 2001 2001

MEDIUM: e-file

PATENT NUMBER: US 6271025 PATENT DATE GRANTED: August 07, 2001 20010807

PATENT CLASSIFICATION: 435-3201 PATENT ASSIGNEE: Aventis Behring GmbH,  
Marburg, Germany PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

**\*Modified\* \*factor\* \*VIII\* cDNA**

ABSTRACT: A \*modified\* \*Factor\* \*VIII\* cDNA is described comprising deletion of the B-domain and insertion of at least one truncated \*Factor\* \*IX\* \*intron\* 1 in the Factor VIII cDNA. The \*modified\* \*Factor\* \*VIII\* cDNA may be used for the production of a high yield of Factor VIII in vitro. The \*modified\* \*Factor\* \*VIII\* cDNA may be incorporated into a vector for gene therapy.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: \*modified\* \*factor\* \*VIII\* complementary DNA  
?ds

Set	Items	Description
S1	3	(FACTOR (W) IX (W) INTRON) (S) (FACTOR (W) VIII)
S2	3	RD (unique items)
S3	16	(MODIFIED OR CHIMERIC) (W) (FACTOR (W) VIII)
S4	1	S3 AND (FACTOR (W) IX (W) INTRON)

?rd s3

...completed examining records

S5 11 RD S3 (unique items)

?t s5/3,k/all

**5/3,K/1 (Item 1 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12612201 PMID: 7730335

**A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells.**

Marquette K A; Pittman D D; Kaufman R J

Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, USA.

Journal of biological chemistry (UNITED STATES) Apr 28 1995, 270 (17)

p10297-303, ISSN 0021-9258 Journal Code: 2985121R

Contract/Grant No.: HL53777; HL; NHLBI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... we have studied the secretion of factor VIII deletion and factor VIII/factor V chimeric proteins upon transient transfection of COS-1 monkey cells. A \*chimeric\* \*factor\* \*VIII\* protein that contained the A1- and A2-domains of factor V was secreted with a similar efficiency as wild-type factor V, whereas the complementary...

**5/3,K/2 (Item 2 from file: 155)**

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11871628 PMID: 12064919

**Expression of factor VIII in recombinant and transgenic systems.**

Soukharev Serguei; Hammond David; Ananyeva Natalya M; Anderson Julia A M; Hauser Charlotte A E; Pipe Steven; Saenko Evgueni L

Department of Plasma Derivatives, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, Maryland 20855, USA.

Blood cells, molecules & diseases (United States) Mar-Apr 2002, 28

(2) p234-48, ISSN 1079-9796 Journal Code: 9509932

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed



Descriptors: Animals, Genetically \*Modified\*; \*\*Factor\* \*VIII\*--genetics  
--GE

5/3,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10704977 PMID: 10821655

**B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol.**

Rostin J; Smeds A L; Akerblom E

Recombinant Factor VIII, R&D, Pharmacia & Upjohn, S-112 87 Stockholm, Sweden.

Bioconjugate chemistry (UNITED STATES) May-Jun 2000, 11 (3) p387-96, ISSN 1043-1802 Journal Code: 9010319

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... blots revealed coupling heterogeneity regarding degree of modification. The amount of factor VIII able to bind to vWf decreased with the conjugation. Thrombin activated the \*modified\* \*factor\* \*VIII\* to essentially the same extent as the reference preparation of r-VIII SQ. Inactivation of the \*modified\* \*factor\* \*VIII\* was, however, slower than inactivation of the unmodified protein. Finally, an in vitro study was performed to evaluate the influence of the mPEG modification on...

5/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

04086401 PMID: 1080490

**Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.**

Cooper H A; Reisner F F; Hall M; Wagner R H

Journal of clinical investigation (UNITED STATES) Sep 1975, 56 (3) p751-60, ISSN 0021-9738 Journal Code: 7802877

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...eluted. In other control experiments, activated and unactivated factor VIII fractions did not clot fibrinogen and contained no assayable factor IX or X. The thrombin-\*modified\* \*factor\* \*VIII\* of small size was inactivated by both a naturally occurring human inhibitor to factor VIII and the gamma globulin fraction of a rabbit antisera produced...

5/3,K/5 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014016139 BIOSIS NO.: 200200609650

**\*Modified\* \*factor\* \*VIII\***

AUTHOR: Lollar John S

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1263 (1): Oct. 1, 2002 2002

MEDIUM: e-file

PATENT NUMBER: US 6458563 PATENT DATE GRANTED: October 01, 2002 20021001

PATENT CLASSIFICATION: 435-696 PATENT ASSIGNEE: Emory University

PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

**\*Modified\* \*factor\* \*VIII\***

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...\*modified\* \*factor\* \*VIII\*--

5/3,K/6 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0013292833 BIOSIS NO.: 200100464672

**\*Modified\* \*factor\* \*VIII\* cDNA**

AUTHOR: Negrier Claude (Reprint); Plantier Jean Luc  
AUTHOR ADDRESS: Irigny, France\*\*France  
JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1249 (1): Aug. 7, 2001 2001  
MEDIUM: e-file  
PATENT NUMBER: US 6271025 PATENT DATE GRANTED: August 07, 2001 20010807  
PATENT CLASSIFICATION: 435-3201 PATENT ASSIGNEE: Aventis Behring GmbH,  
Marburg, Germany PATENT COUNTRY: USA  
ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

**\*Modified\* \*factor\* \*VIII\* cDNA**

ABSTRACT: A \*modified\* \*Factor\* \*VIII\* cDNA is described comprising  
deletion of the B-domain and insertion of at least one truncated Factor  
IX intron 1 in the Factor VIII cDNA. The \*modified\* \*Factor\* \*VIII\* cDNA  
may be used for the production of a high yield of Factor VIII in vitro.  
The \*modified\* \*Factor\* \*VIII\* cDNA may be incorporated into a vector for  
gene therapy.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: \*modified\* \*factor\* \*VIII\* complementary DNA

5/3,K/7 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0012323685 BIOSIS NO.: 200000041998

**Factor VIII - Factor IX interaction probed by \*chimeric\* \*Factor\* \*VIII\*/V  
and Factor IX/X variants: Role of the interface between the two Factor IX  
EGF-like domains in binding to the Factor VIII A3-domain region 1803-1818**

AUTHOR: Mertens K (Reprint); van Stempvoort G; van Mourik J A; Lenting P J;  
Celie P H N  
AUTHOR ADDRESS: Dept. of Plasma Protein Technology, CLB, Amsterdam,  
Netherlands\*\*Netherlands  
JOURNAL: Blood 94 (10 SUPPL. 1 PART 1): p456a Nov. 15, 1999 1999  
MEDIUM: print  
CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of  
Hematology New Orleans, Louisiana, USA December 3-7, 1999; 19991203  
SPONSOR: The American Society of Hematology  
ISSN: 0006-4971  
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster  
RECORD TYPE: Citation  
LANGUAGE: English

**Factor VIII - Factor IX interaction probed by \*chimeric\* \*Factor\* \*VIII\*/V  
and Factor IX/X variants: Role of the interface between the two Factor IX  
EGF-like domains in binding to the Factor VIII A3...**

5/3,K/8 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0005296914 BIOSIS NO.: 198732025805

**STABILITY OF \*MODIFIED\* \*FACTOR\*-\*VIII\* CONCENTRATE BY POLYETHYLENEGLYCOL**  
AUTHOR: SAKURAGAWA N (Reprint); KONDO K; NIWA M; TAKAHASHI K  
AUTHOR ADDRESS: CENTRAL CLINICAL LAB, TOYAMA MED AND PHARMACEUTICAL UNIV,  
TOYAMA, JAPAN\*\*JAPAN  
JOURNAL: Ricerca in Clinica e in Laboratorio 16 (1): p113 1986  
CONFERENCE/MEETING: XVII INTERNATIONAL CONGRESS OF THE WORLD FEDERATION OF  
HEMOPHILIA: PROGRESS IN HEMOPHILIA THROUGH BIOTECHNOLOGY, MILANO, ITALY,  
JUNE 8-13, 1986. RIC CLIN LAB.  
ISSN: 0390-5748  
DOCUMENT TYPE: Meeting  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

**STABILITY OF \*MODIFIED\* \*FACTOR\*-\*VIII\* CONCENTRATE BY POLYETHYLENEGLYCOL**

5/3,K/9 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0002046179 BIOSIS NO.: 197713072171

**IMMUNOLOGICAL STUDIES OF NATIVE AND \*MODIFIED\* \*FACTOR\*-\*VIII\***  
AUTHOR: SWITZER M E; MCKEE P A  
JOURNAL: Circulation Supplement 54 (2): pII-120 1976  
ISSN: 0065-8499  
DOCUMENT TYPE: Article  
RECORD TYPE: Citation  
LANGUAGE: Unspecified

**IMMUNOLOGICAL STUDIES OF NATIVE AND \*MODIFIED\* \*FACTOR\*-\*VIII\***

5/3,K/10 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

02471885 EMBASE No: 1983065896

**Studies on the thrombin-\*modified\* \*factor\* \*VIII\*: Its evidence and  
clinical application**

Urata T.  
II Dep. Intern. Med., Mie Univ. Sch. Med., Tsu Japan  
Mie Medical Journal ( MIE MED. J. ) (Japan) 1982, 32/1 (37-51)  
CODEN: MMJJA  
DOCUMENT TYPE: Journal  
LANGUAGE: ENGLISH

**Studies on the thrombin-\*modified\* \*factor\* \*VIII\*: Its evidence and  
clinical application**

5/3,K/11 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

00581857 EMBASE No: 1976137488

**Effects of thrombin treatment on preparations of factor VIII and the  
Casup 2sup + dissociated small active fragment**  
Cooper H.A.; Reisner F.F.; Hall M.; Wagner R.H.  
Dept. Pathol., Univ. North Carolina Sch. Med., Chapel Hill, N.C. 27514  
United States  
Journal of Clinical Investigation ( J. CLIN. INVEST. ) 1975, 56/3  
(751-760)

CODEN: JCINA  
DOCUMENT TYPE: Journal  
LANGUAGE: ENGLISH

...eluted. In other control experiments, activated and unactivated factor VIII fractions did not clot fibrinogen and contained no assayable factor IX or X. The thrombin \*modified\* \*factor\* \*VIII\* of small size was inactivated by both a naturally occurring human inhibitor to factor VIII and the gamma globulin fraction of a rabbit antisera produced...

?ds

Set	Items	Description
S1	3	(FACTOR (W) IX (W) INTRON) (S) (FACTOR (W) VIII)
S2	3	RD (unique items)
S3	16	(MODIFIED OR CHIMERIC) (W) (FACTOR (W) VIII)
S4	1	S3 AND (FACTOR (W) IX (W) INTRON)
S5	11	RD S3 (unique items)

?logout

04may04 12:48:36 User259876 Session D617.2  
\$1.52 0.476 DialUnits File155  
\$0.84 4 Type(s) in Format 3  
\$0.84 4 Types  
\$2.36 Estimated cost File155  
\$3.83 0.683 DialUnits File5  
\$15.75 9 Type(s) in Format 3  
\$15.75 9 Types  
\$19.58 Estimated cost File5  
\$4.01 0.410 DialUnits File73  
\$5.40 2 Type(s) in Format 3  
\$5.40 2 Types  
\$9.41 Estimated cost File73  
OneSearch, 3 files, 1.569 DialUnits FileOS  
\$1.50 TELNET  
\$32.85 Estimated cost this search  
\$33.23 Estimated total session cost 1.665 DialUnits

### Status: Signed Off. (6 minutes)